Trial · NCT02614456

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

NCT02614456, Phase 1, Completed, Fox Chase Cancer Center

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors. Trials, record NCT02614456. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02614456

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
NCT number: NCT02614456
Status: Completed
Phases: Phase 1
Enrollment: 26 participants, actual
Lead sponsor: Fox Chase Cancer Center
Conditions: Advanced Solid Tumors
Interventions: interferon-gamma and nivolumab
First posted: 2015-11-25
Last updated: 2019-11-29

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Number of participants with treatment-related adverse events as assesses by CTCAE version 4.03.	58 weeks
Primary	Determine the recommended phase 2 dose (RP2D) based on Dose limiting toxicities	6 weeks
Secondary	To evaluate the investigator assessed ORR using standard response evaluation criteria in solid tumors (RECIST) version 1.1 for metastatic renal cell carcinoma.	2 years
Secondary	To evaluate the investigator assessed ORR using standard response evaluation criteria in solid tumors (RECIST) version 1.1 for metastatic urothelial cancer.	2 years
Secondary	To evaluate median progression free survival (PFS) using Kaplan-Meier curves for metastatic renal cell carcinoma.	2 years
Secondary	To evaluate median progression free survival (PFS) using Kaplan-Meier curves for metastatic urothelial cancer.	2 years
Secondary	To evaluate median overall survival (OS) using Kaplan-Meier curves for metastatic renal cell carcinoma.	2 years
Secondary	To evaluate median overall survival (OS) using Kaplan-Meier curves for metastatic urothelial cancer.	2 years
Secondary	To investigate the relationship between PD-L1 expression on tumor cells and on immune cells using IHC and SMI methods.	Baseline
Secondary	To investigate the relationship between PD-L1 expression on tumor cells and on immune cells using IHC and SMI methods.	week 2

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37500647	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02614456

GET https://conductscience.org/api/trials/v1/NCT02614456/registered

API reference For AI assistants